Mark Eller, Ph.D.
Founder, Eller Pharma Consulting
Dr. Eller has 30 years of experience in pharma R&D, 18 as VP/SVP, including leadership roles in both large (Hoechst Marion Roussel, Quintiles) and small-to-midsize pharma (Jazz Pharmaceuticals). His experience encompasses a broad range of therapeutic areas including CNS, oncology, endocrinology, allergy, infectious disease and dermatology. His primary focus is clinical pharmacology, pharmacokinetics and pharmacodynamics.
While at HMR Dr. Eller’s studies with fexofenadine resulted in the patents providing marketing exclusivity for Allegra®. He also helped develop Arava®, Priftin® and Nicoderm®. From 2001 to 2005 Dr. Eller served as Vice President, Clinical Pharmacology at Quintiles, building the department and providing pk/pd support for 10 NDAs. Dr. Eller joined Jazz Pharmaceuticals as Vice President for Research in May 2005, and subsequently served in various positions including Head of R&D Operations and Head of Early Development. His work at Jazz included evaluating assets for potential acquisitions, and lifecycle management activities resulting in revised labeling for Xyrem® and to the 3 “Orange Book” patents with longest coverage. In 2017 Dr. Eller founded Eller Pharma Consulting to provide clients strategic support focused on drug candidate identification, opportunity and risk assessment, and development strategies to minimize the time for completion of trials and regulatory approval.
Dr. Eller has served as Adjunct Professor of Pharmaceutics at the University of Cincinnati and has participated in 6 FDA advisory committee meetings, twice as a primary presenter. He has co-authored numerous scientific publications and is a member of the American Association of Pharmaceutical Scientist and the American Society of Clinical Pharmacology and Therapeutics. Dr. Eller received his Pharmacy degree and Ph.D. in Pharmaceutics from the University of Iowa.